Please login to the form below

Not currently logged in
Email:
Password:

Ariad to commence ponatinib trial for leukaemias

Ariad has announced that it will commence the phase II clinical trial of ponatinib in patients with certain types of leukaemia

Specialising in developing new, breakthrough therapies with the potential to transform the lives of patients with difficult-to-treat cancers, the Massachusetts-based company, Ariad Pharmaceuticals, has announced the initiation of the pivotal phase II clinical trial of its investigational pan-BCR-ABL inhibitor, ponatinib (previously known as AP24534), in patients with resistant or intolerant chronic myeloid leukaemia (CML) and Philadelphia positive acute lymphoblastic leukaemia (Ph+ ALL).

The PACE (Ponatinib Ph+ ALL and CML Evaluation) trial is designed to provide definitive clinical data for regulatory approval of ponatinib in this setting. Ponatinib has been granted orphan drug status in both the US and Europe for the treatment of CML and Ph+ ALL.

"The start of the pivotal PACE trial represents an important step in the development of our second molecularly targeted cancer therapy," said Harvey J Berger, Ariad's MD, chairman and chief executive officer.

"With the strong clinical evidence observed to date of haematologic, cytogenetic and molecular anti-leukaemia activity of ponatinib in heavily pre-treated patients with CML, including those patients with the T315I mutation for whom no current treatments are available, we are highly optimistic about the likelihood of success for ponatinib in this registration trial. We also believe that the time to full patient enrolment in this study and to potential regulatory approval of ponatinib will be swift."

20th September 2010

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

digital healthcare chronic disease
Digital healthcare may revolutionise management of chronic diseases, but who is going to pay for it?
Providers are looking at digital solutions to transform this area of healthcare...
Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...

Infographics